Skip to content Skip to footer
Biopharma Deal Terminations Top 20 2020

Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination.Sanofi and Hanmi's agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology- lapscovery. The second position goes to the…

Read more

Insights+ Key Biosimilars Events of August 2019

Insights+ Key Biosimilars Events of August 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of biosimilar space…

Read more

Insights+ Key Biosimilars Events of July 2019

Insights+ Key Biosimilars Events of July 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' which are biologically like biologics. They possess similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots have…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]